Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response

Antiangiogenic treatment with bevacizumab, a mAb to the VEGF, is the single most widely used therapeutic agent for patients with recurrent glioblastoma. A major challenge is that there are currently no validated biomarkers that can predict treatment outcome. Here we analyze the potential of radiomic...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research Vol. 22; no. 23; pp. 5765 - 5771
Main Authors: Kickingereder, Philipp, Götz, Michael, Muschelli, John, Wick, Antje, Neuberger, Ulf, Shinohara, Russell T, Sill, Martin, Nowosielski, Martha, Schlemmer, Heinz-Peter, Radbruch, Alexander, Wick, Wolfgang, Bendszus, Martin, Maier-Hein, Klaus H, Bonekamp, David
Format: Journal Article
Language:English
Published: United States 01.12.2016
ISSN:1078-0432, 1557-3265
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first